Pure Global AI
NCT06388031Not yet recruiting

ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

A Multicenter, Single-Arm Pilot Study of Immune Checkpoint Inhibitors in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Who Had Long-Term (Two Years or Longer) Response to First-Line Immunotherapy
Peking Union Medical College HospitalPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non-small Cell Lung Cancer
Drug/Device/Intervention
Immune checkpoint inhibitor
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Peking Union Medical College Hospital
Location
Beijing, China
Timeline & enrollment
Phase
Phase 2
Start date
May 10, 2024
End date
Dec 10, 2027
Enrollment
27 participants
Primary outcome

Progression Free Survival (PFS)

Summary

An exploratory phase II trial of immune checkpoint inhibitors (ICIs, anti-PD-1/anti-PD-L1) as
 second-line treatment with advanced non-small cell lung cancer (NSCLC) who had long-term
 response to first-line immunotherapy (with or without chemotherapy).
 
 This study aims to evaluate efficacy and safety of ICI rechallenge in long-term responders to
 prior ICI. Furthermore, it seeks to identify biomarkers capable of predicting the efficacy of
 immunotherapy and prognosis.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06388031
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06388031 through Pure Global AI's free database. This Phase 2 trial is sponsored by Peking Union Medical College Hospital and is currently Not yet recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 27 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.